Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2024-09-11 AGM Information
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Immediate Report of Meeting to be held on October 31, 2024, proxy statement
AGM Information Classification · 1% confidence The document is explicitly titled as a 'Form 6-K' filed with the SEC, which is a general reporting form for Foreign Private Issuers. However, the primary content is the 'NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS' and the accompanying 'PROXY STATEMENT' for a meeting scheduled for October 31, 2024. This material is used to solicit shareholder votes for matters like director elections and compensation policies. According to the definitions, materials shared during the Annual General Meeting (AGM) or the materials used to solicit votes for it fall under AGM Information (AGM-R) or Proxy Solicitation & Information Statement (PSI). Since the document contains both the formal notice/proxy statement and the details of the meeting agenda (which is the core purpose of a proxy statement), PSI is highly relevant, but AGM-R covers the overall event materials. Given the explicit focus on the 'Annual General Meeting of Shareholders' and the inclusion of the proxy statement, AGM-R is the most specific category for the entire package related to the AGM, although PSI is also strongly indicated by the proxy statement content. Since the document is a comprehensive filing (Form 6-K) containing the full AGM notice and proxy statement, and the definition for AGM-R is 'Presentations and materials shared during the Annual General Meeting (AGM)', this classification is appropriate for the core subject matter, which is the AGM itself. The filing date (September 11, 2024) is consistent with pre-AGM solicitation materials.
2024-09-11 English
Immediate Report of Meeting to be held on October 31, 2024, proxy statement
AGM Information Classification · 1% confidence The document explicitly states it is providing notice of the 'convening of meeting' for an 'annual meeting' scheduled for 31/10/2024. It details the agenda items, which primarily concern the re-election of directors and the extension of option terms, typical subjects for an Annual General Meeting (AGM). This content strongly aligns with the definition of AGM Information (AGM-R). Although it is a notice of the meeting, the content provided is the core material (the agenda) for the AGM itself, making AGM-R a more specific fit than a general Report Publication Announcement (RPA) or Regulatory Filing (RNS), especially given the detailed agenda structure.
2024-09-11 English
FINANCIAL STATEMENTS AS OF JUNE 30, 2024
Capital/Financing Update Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," which is the definition of a Form 6-K filing. The content includes detailed "CONDENSED CONSOLIDATED FINANCIAL STATEMENTS" for the three and six month periods ended June 30, 2024, which are typically filed on Form 6-K when a foreign private issuer is reporting interim financial results not otherwise required by US GAAP forms (like 10-Q). Since this document contains the full interim financial statements (Balance Sheets, Statements of Operations, etc.), it is classified as an Interim/Quarterly Report (IR), even though the cover page is Form 6-K, as IR is the category for comprehensive period reports shorter than a year. The presence of detailed financial statements and the reporting period (six months ended June 30) strongly points to IR over a general regulatory filing (RNS).
2024-08-31 English
FINANCIAL STATEMENTS AS OF JUNE 30, 2024
Report Publication Announcement Classification · 1% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Israeli Securities Authority regulations. It mentions an attached file named '*6k30082024_isa.pdf*' and references the SEC Form 6-K, which is used by foreign private issuers to report material events. Since this document is short (1880 chars) and its primary function is to announce the publication of an attached periodic report (likely a 6-K filing, which is similar in function to an IR or ER but specific to foreign issuers reporting material events), it fits the description of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The 'Menu vs Meal' rule applies here: this is the announcement of the report, not the report content.
2024-08-31 English
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," which is filed on Form 6-K. Form 6-K filings are typically used by foreign private issuers to report material information to the SEC, often mirroring press releases or other material events. The content is a press release announcing regulatory authorization for a Phase I clinical trial, which is a material event. While the content resembles an Earnings Release (ER) or a general Regulatory Filing (RNS), the primary structure and context identify it as a Form 6-K submission. In the provided classification scheme, Form 6-K does not have a direct mapping. However, since it is a formal, periodic/event-driven filing containing material information that is not a full annual report (10-K), interim report (IR), or earnings release (ER) (which usually contains summarized financials), it best fits the general category for regulatory filings that don't fit elsewhere, which is RNS (Regulatory Filings). Given the specific nature of the Form 6-K structure, RNS is the most appropriate fallback, although it is a very specific type of regulatory submission.
2024-07-23 English
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k23072024_isa.pdf*". This structure indicates that the current document is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for material events). According to Rule 2, when a document is short and announces the availability of the main report, it should be classified as a Report Publication Announcement (RPA). Since it is a regulatory filing announcement that doesn't fit a more specific category like DIV or ER, RPA is the most appropriate classification based on the 'Menu vs Meal' rule.
2024-07-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.